Screening of Biomarkers and Quality Control of Shaoyao Gancao Decoction Using UPLC-MS/MS Combined with Network Pharmacology and Molecular Docking Technology

Table 4

The first 20 key targets of SGD in treating liver injury.

No.	Target name	Betweenness centrality	Closeness centrality	Degree
1	EGFR	0.0461	0.6045	104
2	CTNNB1	0.0527	0.5978	101
3	HSP90AA1	0.0561	0.5833	94
4	SRC	0.0239	0.5821	93
5	HRAS	0.0260	0.5600	86
6	STAT3	0.0176	0.5588	83
7	MAPK1	0.0232	0.5485	75
8	PIK3CA	0.0051	0.5086	59
9	FGF2	0.0047	0.5165	58
10	APP	0.0276	0.5341	56
11	BCL2L1	0.0050	0.5236	54
12	GSK3B	0.0059	0.5175	51
13	KDR	0.0035	0.5135	49
14	NRAS	0.0034	0.4926	49
15	IL2	0.0047	0.5057	49
16	ACE	0.0167	0.5096	47
17	MMP2	0.0020	0.5076	45
18	RELA	0.0067	0.5106	44
19	KIT	0.0033	0.4953	43
20	PRKCA	0.0078	0.5076	43